$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

$rigl Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-K Financial Statement

#000104746913002185 Filed on March 05, 2013

Income Statement

Concept	2013 Q1	2012	2011 Q4
Revenue	$0.00	$2.300M	$0.00
YoY Change	-100.0%	-52.08%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.400M	$22.80M	$6.090M
YoY Change	-12.34%	4.59%	3.05%
% of Gross Profit
Research & Development	$20.32M	$78.78M	$19.82M
YoY Change	13.47%	13.59%	44.04%
% of Gross Profit
Depreciation & Amortization	$669.0K	$2.433M	$530.0K
YoY Change	21.2%	24.45%	32.5%
% of Gross Profit
Operating Expenses	$20.32M	$78.78M	$25.91M
YoY Change	13.47%	13.59%	31.72%
Operating Profit	-$25.71M	-$99.38M
YoY Change	10.3%	15.06%
Interest Expense	$140.0K	$500.0K	$120.0K
YoY Change		1900.0%	71.43%
% of Operating Profit
Other Income/Expense, Net		$0.00	$0.00
YoY Change			-100.0%
Pretax Income	-$25.57M	-$98.80M	-$25.79M
YoY Change	10.36%	14.92%	49.59%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$25.57M	-$98.80M	-$25.79M
YoY Change	10.36%	14.88%	49.59%
Net Earnings / Revenue		-4295.65%
Basic Earnings Per Share		-$1.32
Diluted Earnings Per Share	-$293.4K	-$1.32	-$360.5K
COMMON SHARES
Basic Shares Outstanding	87.14M shares	74.97M shares	71.24M shares
Diluted Shares Outstanding		74.97M shares

Balance Sheet

Concept	2013 Q1	2012	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$272.5M	$298.2M	$247.6M
YoY Change	22.01%	20.44%	39.67%
Cash & Equivalents	$34.16M	$33.50M	$18.63M
Short-Term Investments	$238.3M	$264.8M	$229.0M
Other Short-Term Assets	$3.000M	$4.200M	$2.600M
YoY Change	7.14%	61.54%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$275.4M	$302.5M	$250.2M
YoY Change	21.82%	20.9%	39.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.833M	$5.800M	$4.882M
YoY Change	-1.2%	18.37%	7.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.701M	$1.800M	$1.991M
YoY Change	-11.96%	-10.0%	-10.92%
Total Long-Term Assets	$7.495M	$7.500M	$6.873M
YoY Change	-4.35%	8.7%	1.54%
TOTAL ASSETS
Total Short-Term Assets	$275.4M	$302.5M	$250.2M
Total Long-Term Assets	$7.495M	$7.500M	$6.873M
Total Assets	$282.9M	$310.0M	$257.1M
YoY Change	20.94%	20.58%	37.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.138M	$1.700M	$1.556M
YoY Change	11.24%	6.25%	10.91%
Accrued Expenses	$6.200M	$9.800M	$9.800M
YoY Change	5.08%	0.0%	6.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.158M	$12.20M	$11.53M
YoY Change	13.92%	6.09%	1.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$91.00K	$8.700M	$117.0K
YoY Change	-18.75%	-7.45%	-14.6%
Total Long-Term Liabilities	$91.00K	$8.700M	$117.0K
YoY Change	-18.75%	-7.45%	-14.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.158M	$12.20M	$11.53M
Total Long-Term Liabilities	$91.00K	$8.700M	$117.0K
Total Liabilities	$9.249M	$20.90M	$11.64M
YoY Change	13.47%	-0.48%	1.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$785.8M		-$661.4M
YoY Change	14.79%		14.94%
Common Stock	$1.051B		$897.6M
YoY Change	16.64%		21.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$265.3M	$289.1M	$236.1M
YoY Change
Total Liabilities & Shareholders Equity	$282.9M	$310.0M	$257.1M
YoY Change	20.96%	20.58%	37.71%

Cashflow Statement

Concept	2013 Q1	2012	2011 Q4
OPERATING ACTIVITIES
Net Income	-$25.57M	-$98.80M	-$25.79M
YoY Change	10.36%	14.88%	49.59%
Depreciation, Depletion And Amortization	$669.0K	$2.433M	$530.0K
YoY Change	21.2%	24.45%	32.5%
Cash From Operating Activities	-$25.11M	-$85.21M	-$18.66M
YoY Change	7.91%	22.82%	-281.87%
INVESTING ACTIVITIES
Capital Expenditures	$676.0K	$3.377M	-$180.0K
YoY Change	-57.05%	46.63%	-80.65%
Acquisitions
YoY Change
Other Investing Activities	$26.46M	-$35.66M	$18.02M
YoY Change	-4.68%	-41.11%	-178.28%
Cash From Investing Activities	$25.79M	-$39.03M	$17.83M
YoY Change	-1.53%	-37.9%	-174.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$139.1M
YoY Change		-2.58%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	139.1M	770.0K
YoY Change	-100.0%	-2.04%	50.98%
NET CHANGE
Cash From Operating Activities	-25.11M	-85.21M	-18.66M
Cash From Investing Activities	25.79M	-39.03M	17.83M
Cash From Financing Activities	0.000	139.1M	770.0K
Net Change In Cash	680.0K	14.85M	-60.00K
YoY Change	-80.06%	52.31%	-99.54%
FREE CASH FLOW
Cash From Operating Activities	-$25.11M	-$85.21M	-$18.66M
Capital Expenditures	$676.0K	$3.377M	-$180.0K
Free Cash Flow	-$25.79M	-$88.59M	-$18.48M
YoY Change	3.79%	23.58%	-265.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8647000	USD
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	289096000	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	250233000	USD
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1991000	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Assets Assets	310043000	USD
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7271000	USD
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	504000	USD
CY2011Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	129000	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11527000	USD
CY2011Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9313000	USD
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	117000	USD
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1556000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18633000	USD
CY2011Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	229007000	USD
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2593000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4882000	USD
CY2011Q4	us-gaap	Assets Assets	257106000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	71000	USD
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	897479000	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-661407000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	236149000	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	257106000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	302458000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12204000	USD
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-53403000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	310043000	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87140632	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87140632	shares
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71379052	shares
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71379052	shares
CY2011	us-gaap	Contracts Revenue ContractsRevenue	4750000	USD
CY2010	us-gaap	Contracts Revenue ContractsRevenue	125000000	USD
CY2011	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	69350000	USD
CY2010	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	64392000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21768000	USD
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25291000	USD
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	91118000	USD
CY2010	us-gaap	Costs And Expenses CostsAndExpenses	89683000	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	101627000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-86368000	USD
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	35317000	USD
CY2010	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2361000	USD
CY2011	us-gaap	Investment Income Interest InvestmentIncomeInterest	420000	USD
CY2010	us-gaap	Investment Income Interest InvestmentIncomeInterest	303000	USD
CY2011	us-gaap	Interest Expense InterestExpense	25000	USD
CY2010	us-gaap	Interest Expense InterestExpense	91000	USD
CY2012	rigl	Effective Income Tax Rate Reconciliation True Up Of Prior Year Net Operating Loss EffectiveIncomeTaxRateReconciliationTrueUpOfPriorYearNetOperatingLoss	-0.114	pure
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-85973000	USD
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	37890000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-98840000	USD
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.73
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.72
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74967000	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74967000	shares
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63329000	shares
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52055000	shares
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63329000	shares
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52573000	shares
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1955000	USD
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1317000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	13168000	USD
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	16436000	USD
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-38000	USD
CY2010	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-5840000	USD
CY2011	us-gaap	Interest Paid InterestPaid	21000	USD
CY2010	us-gaap	Interest Paid InterestPaid	84000	USD
CY2010	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	98000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1624000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	139094000	USD
CY2012	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	14851000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8877000	USD
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14717000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33484000	USD
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	109867000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	166131000	USD
CY2011	rigl	Effective Income Tax Rate Reconciliation True Up Of Prior Year Net Operating Loss EffectiveIncomeTaxRateReconciliationTrueUpOfPriorYearNetOperatingLoss	0.000	pure
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-19000	USD
CY2011	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-244000	USD
CY2010	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-250000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	153000	USD
CY2010	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1751000	USD
CY2011	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2460000	USD
CY2010	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2029000	USD
CY2010	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2000	USD
CY2011	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-402000	USD
CY2011	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	366000	USD
CY2010	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-3028000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-69375000	USD
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	46743000	USD
CY2011	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	476038000	USD
CY2010	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	266092000	USD
CY2011	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	415493000	USD
CY2010	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	216249000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2303000	USD
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3560000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-62848000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	139094000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-85192000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-39051000	USD
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	800000	USD
CY2010	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1144000	USD
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	142779000	USD
CY2010	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1964000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	141979000	USD
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	820000	USD
CY2011	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	9756000	USD
CY2010	rigl	Effective Income Tax Rate Reconciliation True Up Of Prior Year Net Operating Loss EffectiveIncomeTaxRateReconciliationTrueUpOfPriorYearNetOperatingLoss	0.000	pure
CY2010	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-26000	USD
CY2012Q4	rigl	Acrrued Research And Development Liability Current AcrruedResearchAndDevelopmentLiabilityCurrent	2124000	USD
CY2011	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	44000	USD
CY2011Q4	rigl	Acrrued Research And Development Liability Current AcrruedResearchAndDevelopmentLiabilityCurrent	2067000	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140505000	USD
CY2010	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1964000	USD
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2274000	USD
CY2012	dei	Entity Registrant Name EntityRegistrantName	RIGEL PHARMACEUTICALS INC
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0001034842
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b>Financial statement preparation</b></font></p> <p style="FONT-FAMILY: times"><font size="2">        The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made by management include those relating to the terms of our research and development collaborations (i.e. revenue recognition of upfront fees and certain contingent payments), investments, stock-based compensation, impairment issues, estimated useful life of assets, estimated accruals, particularly research and development accruals, and potential loss contingencies. We believe that the estimates and judgments upon which we rely are reasonable based upon information available to us at the time that these estimates and judgments are made, however actual results could differ from these estimates. To the extent there are material differences between these estimates and actual results, our financial statements will be affected.</font></p></div>
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b>Concentration of credit risk</b></font></p> <p style="FONT-FAMILY: times"><font size="2">        Financial instruments that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and available-for-sale securities. Cash equivalents and available-for-sale securities primarily consist of money market funds, U. S. treasury bills, government-sponsored enterprise securities, and corporate bonds and commercial paper. Due to the mostly short-term nature of these investments, we believe we do not have a material exposure to credit risk arising from our investments. All cash and cash equivalents and available-for-sale securities are maintained with financial institutions that management believes are creditworthy.</font></p></div>
CY2012	rigl	Share Based Compensation Number Of Stock Option Plans ShareBasedCompensationNumberOfStockOptionPlans	3	item
CY2010	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	518000	shares
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12617000	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13168000	USD
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16436000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	23118000	USD
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	264757000	USD
CY2012Q4	rigl	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	19813000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	273972000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	135000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	53000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure	274054000	USD
CY2012	rigl	Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Homogenous Groups For Determining Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfHomogenousGroupsForDeterminingFairValue	3	item
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	27420000	USD
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	243604000	USD
CY2012	rigl	Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod	P212D
CY2012	rigl	Available For Sale Securities Debt Securities Current Stated Maturity Period May Be Greater Than This Period AvailableForSaleSecuritiesDebtSecuritiesCurrentStatedMaturityPeriodMayBeGreaterThanThisPeriod	P1Y
CY2012Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions	25	item
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	78511000	USD
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	53000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4145000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	283268000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	283268000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26062000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23102000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20236000	USD
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18220000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5826000	USD
CY2011	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	206000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2433000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	13809000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	14351000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	14929000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	15530000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	16153000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	76123000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	51700000	USD
CY2012	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	2500000	USD
CY2012Q4	rigl	Deferred Tax Assets Operating Loss Carryforwards Not Included DeferredTaxAssetsOperatingLossCarryforwardsNotIncluded	1700000	USD
CY2012	rigl	Deferred Tax Assets Operating Loss Carryforwards Not Included Effect On Equity If Realized DeferredTaxAssetsOperatingLossCarryforwardsNotIncludedEffectOnEquityIfRealized	1700000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	14700000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	14800000	USD
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	15200000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	24607000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4168000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	231533000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	231533000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.336	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.004	pure
CY2012Q2	dei	Entity Public Float EntityPublicFloat	662418484	USD
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87140632	shares
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	163747000	USD
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	19997000	USD
CY2011Q4	rigl	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	19014000	USD
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.336	pure
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004	pure
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	942000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	666000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	96000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1049174000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	82000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-760247000	USD
CY2012	us-gaap	Contracts Revenue ContractsRevenue	2250000	USD
CY2012	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	78778000	USD
CY2011Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2011	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	34500000	USD
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2011	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	2500000	USD
CY2012	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	57000	USD
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
CY2011Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71422000	shares
CY2011Q2	us-gaap	Contracts Revenue ContractsRevenue	395000	USD
CY2011Q3	us-gaap	Contracts Revenue ContractsRevenue	4355000	USD
CY2012Q1	us-gaap	Contracts Revenue ContractsRevenue	750000	USD
CY2012Q2	us-gaap	Contracts Revenue ContractsRevenue	1500000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23174000	USD
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24738000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25456000	USD
CY2012Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25472000	USD
CY2011Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20781000	USD
CY2011Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21474000	USD
CY2011Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17931000	USD
CY2011Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25787000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	87000	USD
CY2012	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	76000	USD
CY2011	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	-1384000	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	135729000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	12617000	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3365000	USD
CY2012Q4	rigl	Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent	298241000	USD
CY2011Q4	rigl	Cash And Cash Equivalents And Available For Sale Securities Debt Securities Current CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesCurrent	247640000	USD
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71458000	shares
CY2011Q4	rigl	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	235001000	USD
CY2011Q4	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	76000	USD
CY2011Q4	rigl	Cash Equivalents And Available For Sale Securities Gross Unrealized Losses CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLosses	70000	USD
CY2011Q4	rigl	Cash Equivalents And Available For Sale Securities Debt Securities Unrealized Gain Loss Fair Value Disclosure CashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesUnrealizedGainLossFairValueDisclosure	235007000	USD
CY2011Q4	rigl	Deferred Tax Assets Operating Loss Carryforwards Not Included DeferredTaxAssetsOperatingLossCarryforwardsNotIncluded	1700000	USD
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71636000	shares
CY2012Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85274000	shares
CY2011	rigl	Deferred Tax Assets Operating Loss Carryforwards Not Included Effect On Equity If Realized DeferredTaxAssetsOperatingLossCarryforwardsNotIncludedEffectOnEquityIfRealized	1700000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4217000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1759000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1697000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6775000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22849000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-99377000	USD
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	537000	USD
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-232000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	141000	USD
CY2012	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-496000	USD
CY2012	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	438000	USD
CY2012	rigl	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-150000	USD
CY2012	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	475398000	USD
CY2012	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	439724000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3377000	USD
CY2011Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52275000	shares
CY2011Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58272000	shares
CY2011Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71226000	shares
CY2011Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71249000	shares
CY2012	rigl	Operating Leases Additional Period Under Renewal Option OperatingLeasesAdditionalPeriodUnderRenewalOption	P5Y
CY2012Q4	rigl	Operating Leases Number Of Additional Periods Under Renewal Option OperatingLeasesNumberOfAdditionalPeriodsUnderRenewalOption	2	item
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-98764000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85929000	USD
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	37864000	USD
CY2012	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	422000	USD
CY2012	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment	417000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	208772000	USD
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.340	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.475	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.021	pure
CY2012Q4	rigl	Unrecognized Tax Benefits That Would Impact Other Tax Accounts Including Deferred Taxes UnrecognizedTaxBenefitsThatWouldImpactOtherTaxAccountsIncludingDeferredTaxes	3300000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	200000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4300000	USD
CY2010	rigl	Increase Decrease In Accrued Research And Development Liability IncreaseDecreaseInAccruedResearchAndDevelopmentLiability	-2363000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2600000	USD
CY2011Q4	rigl	Unrecognized Tax Benefits That Would Impact Other Tax Accounts Including Deferred Taxes UnrecognizedTaxBenefitsThatWouldImpactOtherTaxAccountsIncludingDeferredTaxes	1000000	USD
CY2011	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	8.00
CY2012	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	9.50
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.00	pure
CY2012Q4	rigl	Cash Equivalents And Available For Sale Securities Debt Maturities Rolling Year Two Fair Value CashEquivalentsAndAvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoFairValue	54386000	USD
CY2011	us-gaap	Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment	206000	USD
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1351000	USD
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	17470710	shares

Files In Submission

Name	View Source	Status
0001047469-13-002185-index-headers.html	Edgar Link	pending
0001047469-13-002185-index.html	Edgar Link	pending
0001047469-13-002185.txt	Edgar Link	pending
0001047469-13-002185-xbrl.zip	Edgar Link	pending
a2213009z10-k.htm	Edgar Link	pending
a2213009zex-23_1.htm	Edgar Link	pending
a2213009zex-31_1.htm	Edgar Link	pending
a2213009zex-31_2.htm	Edgar Link	pending
a2213009zex-32_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g583866.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rigl-20121231.xml	Edgar Link	completed
rigl-20121231.xsd	Edgar Link	pending
rigl-20121231_cal.xml	Edgar Link	unprocessable
rigl-20121231_def.xml	Edgar Link	unprocessable
rigl-20121231_lab.xml	Edgar Link	unprocessable
rigl-20121231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl

2013 Q1 Form 10-K Financial Statement

#000104746913002185 Filed on March 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL RIGEL PHARMACEUTICALS INC Stock $rigl

2013 Q1 Form 10-K Financial Statement

#000104746913002185 Filed on March 05, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RIGL
RIGEL PHARMACEUTICALS INC Stock $rigl